In North America, more than 5 million patients per year present to the emergency department (ED) with acute chest pain [1] . Early triage is essential for both prognosis and treatment; however, current management methods do not effectively assess those patients in whom initial cardiac biomarkers and electrocardiogram (ECG) changes are inconclusive. Although 80% of patients admitted to the hospital undergo extensive testing, which often prove noncardiac causes of chest pain, 2%-8% of discharged patients inadvertently have acute coronary syndrome (ACS) [2] .
At the same time, it is important to note that chest pain may result from a broad range of etiologies, including cardiac, pulmonary, musculoskeletal, and psychological origins. As such, a thorough history and physical examination of the patient should be undertaken to narrow the differential diagnosis before imaging is requested. In this way, clinicians may be able to arrive at a diagnosis without the need for unnecessary imaging studies.
Recent advances in multidetector computed tomography (MDCT) and the advent of the triple-rule-out (TRO) protocol provide noninvasive visualization of coronary and/or pulmonary arteries, thoracic aorta, and the other intrathoracic structures. By evaluating both coronary and noncoronary disease, the TRO scan provides a cost-effective diagnostic study for acute chest pain [3] . The aim of this article is to provide an overview of the imaging modalities used in the evaluation of patients presenting with acute chest pain, with a focus on the role and added value of MDCT.
Initial Assessment
Traditionally, the initial assessment in the ED entails a thorough history, physical examination, and ECG, as well as measurement of cardiac biomarkers. However, up to 28% of patients present with atypical chest pain or delayed findings [4] , which limit the sensitivity of traditional assessments. Up to 20% of patients with ACS have atypical or nonexistent chest pain, and up to 10% of patients initially diagnosed with an myocardial infarction are later found to have normal or nonspecific ECG findings [4] . Moreover, the measurement of troponin has high specificity but low sensitivity for an ACS in the initial hours of presentation.
Due to these diagnostic errors, the American College of Cardiology (ACC) and American Heart Association (AHA) have published guidelines on risk stratification for patients with ACS. Patients in the first category (low risk) and second category (high risk) pose no major difficulty to diagnosis and treat [5] . However, patients in the third category (intermediate risk) are more difficult to triage [5] . This group consists of patients often in their fourth through sixth decade of life, with findings that tend to be indeterminate, nonspecific, or atypical, with few if any risk factors. Imaging has the greatest potential for risk stratification and clinical decision making in this challenging category.
Standard Diagnostic Testing
Current AHA-ACC guidelines recommend a multimodal approach to diagnostic testing [5] . For early triage, functional tests are of limited value because of the requirement for serial negative biomarkers, the specific expertise of personnel, and the frequency of nondiagnostic tests [1] . The indications, advantages, and disadvantages for the current diagnostic tests used in the ED to triage patients with chest pain are described in Table 1 [1,4,6e9] . A TRO scan performed for atypical chest pain with normal ECG is demonstrated in Figure 1 .
MDCT
Although the aforementioned modalities provide valuable information for risk stratification, the diagnostic accuracy for chest pain is limited. Recent advances in MDCT, rapid scan times of less than 5-10 seconds, excellent temporal and spatial resolution, simple handling of large data sets, and easy postprocessing capabilities, make MDCT an attractive modality for triaging patients with chest pain, with an intermediate probability of coronary artery disease (CAD) [1] . According to White and Kuo [4] , initial evaluation with MDCT reduces diagnostic times by 11.6 hours compared with traditional diagnostic testing (3.4 hours vs 15 hours). In addition, the average cost per patient is significantly reduced, and patients require fewer subsequent evaluations for recurrent chest pain [3, 4] . Sensitivity and specificity of ECGgated 64-section CT angiography for significant coronary artery stenosis (>50% diameter reduction) are 86%-100% and 92%-98%, respectively [3] . Data can be acquired by scanning dedicated to coronary arteries or, alternatively, with the TRO protocol, scanning the whole chest. The utility of MDCT in making a diagnosis in patients presenting to the ED with atypical chest pain is demonstrated in Figures 2-4 .
Dedicated Coronary CT
A dedicated coronary CT angiogram (CTA) performed by the newest MDCT scanners provides high-quality images of the coronary arteries but allows limited visualization of other structures that may be the culprit for the chest pain [4] .
TRO Protocol
A 64-MDCT now enables combined imaging of the coronary and/or pulmonary arteries and the thoracic aorta [3] , which provides a tool to rule out a broader spectrum of potentially life-threatening causes of chest pain, including pulmonary embolism, aortic dissection, and coronary artery disease. In low-to-intermediate risk patients whose diagnosis and management is indeterminate, the TRO protocol can be used to rapidly rule out ACS as well as to evaluate for other causes of chest pain [3] .
The design of an algorithm for a single acquisition that yields the most useful diagnostic information is a balance between a dedicated coronary CT angiography (ECG-gated, restricted field of view, and limited cephalocaudal coverage), and a chest CT protocol used for noncoronary causes of chest pain (non-ECG gated, larger field of view, and greater longitudinal coverage) [4] . Principal disadvantages with the TRO protocol are possibly less optimal visualization of the coronary arteries and the higher dose of radiation [4] . Patient selection, scan parameters, and contrast infusion rates of the TRO protocol at our institution are shown in Tables 2-4 [3, 10] .
Low-Dose MDCT Protocol
High spatial and temporal resolution required for accurate assessment of coronary artery stenosis translates into an increased radiation dose. A balance between optimal dose savings and diagnostic image quality must be obtained [1] .
The most effective way to reduce radiation dose is through ECG-dependent modulation of the tube current, because images are primarily obtained during diastole (least amount of coronary artery motion), whereas tube current is reduced by 80% during systole [1] . Compared with a typical coronary CTA, the use of this algorithm reduces the overall radiation dose by 37% [1] . Other strategies to reduce radiation include changing scanning protocols according to body habitus of patients (>85 kg or body mass index > 30 kg/m 2 by using 120 kV and 350 reference mAs and in patients <85 kg or body mass index < 30 kg/m 2 by using 100 kV and 250 reference mAs) reduce doses up to 50% by using high pitch values such as 3.2 on new scanners because pitch is inversely related to dose in cardiac imaging, and modulating the tube current for the whole chest in TRO scan (see Table 3 for parameters).
Conclusion
MDCT provides an excellent means of noninvasively triaging patients with acute chest pain with a low-tointermediate risk of ACS. The TRO protocol can be a powerful means for evaluating patients with acute atypical chest pain by ascertaining a cause for the chest pain, which results in better patient management and can lead to improved patient outcomes. Overall, when compared with conventional management of acute chest pain, the TRO strategy can reduce the time for patient triage, number of unnecessary diagnostic tests, and ED costs. The major limitations for wide-spread acceptance of this test include increased radiation exposure and motion artifacts, and its suboptimal imaging with increased body mass index [11] .
However, by using the low-dose TRO, radiation exposure can be significantly reduced, from 20 to 25 mSv down to 4 to 5 mSv, a 4-fold reduction in dose [9] . 
